Risedronate Sodium NDC 59762-0407

NDC codes

FDA NDC Directory

Product NDC (as listed)59762-0407Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59762-0407Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59762-0407-4	59762040704	4 TABLET, DELAYED RELEASE in 1 DOSE PACK (59762-0407-4)Marketed from Mar 2, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Risedronate Sodium
Generic name (nonproprietary): risedronate sodium
Active ingredients: Risedronate sodium hemipentahydrate — 30.1 mg/1Risedronate sodium monohydrate — 4.9 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: Mylan Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 022560
Marketing start: Mar 2, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)Diphosphonates (Chemical structure)
Identifiers: Product ID 59762-0407_b7e3ea01-4634-467a-b087-3d52ef7af465SPL ID b7e3ea01-4634-467a-b087-3d52ef7af465SPL set ID c89430be-15f1-4b8b-ab7e-738de716ee7dRxCUI 1020064, 1020065UNII HU2YAQ274O, F67L43UT5C
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459762040704 followed by a unit qualifier and the quantity

Package 59762-0407-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 3, 2026.

Indications (excerpt from the label)

Risedronate sodium is a bisphosphonate in a delayed-release formulation and is indicated for treatment of postmenopausal osteoporosis ( 1.1 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.2 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium delayed-release is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [ see Clinical Studies (14.1) ] . 1.2 Important Limitations of Use The…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022560

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022560
Product	Strength	Form · route	Labeler	Product NDC
Atelviarisedronate sodium	Risedronate sodium hemipentahydrate 30.1 mg/1; Risedronate sodium monohydrate 4.9 mg/1	Tablet, Delayed releaseOral	Allergan, Inc.	0430-0979